Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Detailed Description
-----------------
This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Official Title
-----------------
To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )

Conditions
-----------------
Malignant Pleural Mesotheliomas

Intervention / Treatment
-----------------
* Other: marker CD74 and vascular endothelial growth factor VEGF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histopathological confirmation of malignant pleural mesothelioma . Full clinical data. Availability for follow up: Personal communication will be attempted in order to collect missing information. 3-The files of all patients will be reviewed to analyze the following : Operative data if done . Pathological review and immunohistochemistry. Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test) Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ). Treatment protocols applied: Radiotherapy and Chemotherapy. Response and survival after treatment . Exclusion Criteria: cases not receive chemotherapy ,on available of evaluation after treatment

Ages Eligible for Study
-----------------
Minimum Age: 39 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival | The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment | 3-4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74 | The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment | 3-4 months |